HCV protease inhibitor and NS5A inhibitor combination

This page covers all HCV protease inhibitor and NS5A inhibitor combination drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting HCV NS3/4A protease, HCV NS5A protein.

Targets

HCV NS3/4A protease, HCV NS5A protein

Marketed (1)

• Ombitasvir-Paritaprevir-Ritonavir · University of Modena and Reggio Emilia · Virology/Hepatology
  This combination inhibits hepatitis C virus NS3/4A protease, NS5A protein, and uses ritonavir as a pharmacokinetic booster to increase drug levels.

Patent intelligence

• hcv protease inhibitor and ns5a inhibitor combination patent landscape — aggregated cliff calendar, attackable patents, originator estates